Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Keeps you up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
3 Thoughts on the FDA’s Final LDTs Rule
Regulatory expert Julie Ballard shares her first thoughts on the final rule for lab-developed tests and immediate steps for labs
HHS Secretary Calls for Bi-Partisan Efforts to Improve Health Care
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence Health and Human Services Secretary Sylvia Matthews Burwell recently delivered a speech to the New America Foundation calling for Congress and the Administration to work together to capitalize on...
Medicare Fee-For-Service is Top of List for Fraud, Waste and Abuse
By Christopher P. Young, Editor, G2 Compliance Advisor Medicare fee-for-service (FFS) tops a list of 13 high error rate government programs estimated to have lost $106 billion during fiscal year 2013 to improper payments. According to the authors of a study by...
Obama Touts Precision Medicine Initiative in State of the Union
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies President Barack Obama announced a new precision medicine initiative this week in his State of the Union Address. Also known as personalized medicine, expanding the government's focus on...
DNA-Based HPV Test OK For Primary Screening
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies DNA-based human papillomavirus tests can be used as a primary screening tool for cervical cancer in women 25 years of age and older, according to a controversial interim guidance published...
Cleveland HeartLab Acquires Proprietary Cardiac Risk Algorithm Technology
By Ron Shinkman, Editor, Laboratory Industry Report The Ohio-based Cleveland HeartLab (CHL) has acquired technology developed by Stanford University that can more accurately predict the likelihood of heart attacks. Known as MIRISK, its nucleus is an algorithm that...
Roche to Take Majority Stake in Foundation Medicine
By Stephanie Murg, Managing Director, G2 Intelligence Roche is betting big on cancer genomics. The Swiss pharmaceutical giant has agreed to acquire a majority stake in Foundation Medicine (Cambridge, Mass.), which uses genetic sequencing to optimize treatment...
Pharmaceutical Company Uses Speaker Fees To Provide Kickbacks
By Christopher P. Young, Editor, G2 Compliance Advisor Pharmaceutical company Daiichi Sankyo Inc. paid $39 million and agreed to enter into a five-year Corporate Integrity Agreement to settle government allegations of using speaker fees and lavish dinners as a...
FDA Workshop Continues the Debate About LDT Regulation
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence The debate regarding FDA regulation of laboratory developed tests (LDTs) continues to swirl as the FDA held a two-day workshop providing a forum for public comment from more than 80 presenters. The...